证券代码：301075 证券简称：多瑞医药 公告编号：2025-077 西藏多瑞医药股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现金 管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 四、 投资风险分析及风险控制措施 公司进行现金管理购买的产品属于安全性高的投资品种，但不排 除该项投资受到市场波动的影响。针对可能发生的收益风险，公司制 定如下措施： 1、在确保不影响公司正常生产经营的基础上，根据公司闲置募 集资金情况，针对投资产品的安全性、期限和收益情况选择合适的产 品。 2、公司财务部将及时与银行核对账户余额，做好财务核算工作， 一旦发现存在可能影响公司资金安全的风险因素将及时采取保全措 施，控制投资风险，并对所投资产品的资金使用和保管进行实时分析 和跟踪。 3、公司内审部门负责投资理财产品与保管情况的审计监督，定 序 号 购买 主体 受托方名称 产品名称 金额 （万 元） 产品 类型 产品起 息日 产品 到期日 预期年 化收益 率 赎回本 金（万 元） 投资收 益（元） 1 湖北多 瑞药业 有限公 司 中国民生银 行股 ...

Key Points - Hainan Huatie's shareholder Hu Danfeng has terminated the share reduction plan and plans to increase holdings in the company with an investment of no less than 30 million yuan and no more than 50 million yuan [2] - Yonghe Co. expects a net profit increase of 447.64% to 506.85% year-on-year for Q3 2025, driven by the high demand in the refrigerant industry and product optimization [3] - Delis Co. is planning a change in company control, leading to a suspension of its stock from October 9, 2025 [4] - BYD reported September 2025 sales of 396,300 new energy vehicles, a slight decrease from 419,400 units in the same month last year, while cumulative sales for the year reached 3.26 million units, up 18.64% [5] - Chipone Technology expects Q3 2025 revenue of 1.284 billion yuan, marking a historical high for the company, with a year-on-year increase of 78.77% [7] - Chipone anticipates a significant improvement in profitability for Q3 2025, with new orders expected to reach 1.593 billion yuan, a year-on-year increase of 145.80% [8] - ST Zhengping's stock will be suspended from trading starting October 9, 2025, due to unusual stock price fluctuations [2][28] - Huanxin Cement plans to repurchase shares worth between 32.25 million and 64.5 million yuan [14] - Sichuan Gold won exploration rights for a gold mine in Xinjiang for 510 million yuan, indicating strong geological potential [15]

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [4] - Bee Assistant plans to raise no more than 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [5] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [6] - Three squirrels have received approval from the China Securities Regulatory Commission for H-share issuance, with plans to issue up to 81.5483 million shares [7] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [8] Group 2 - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind, solar, and energy storage [9] - Sains plans to invest no more than 300 million yuan in the expansion of its selection agent project [10] Group 3 - Hunan YN reports no significant changes in its internal and external operating environment [11] - Electric Power Investment has had its major asset replacement review suspended by the Shenzhen Stock Exchange due to expired financial documents [12] - Guanzhong Ecological is in the planning stage for acquiring a 51% stake in Hangzhou Actuary [13][14] Group 4 - Aima Technology's subsidiary is transferring production capacity and ceasing operations due to strategic adjustments [17] - Fosun Pharma's subsidiary has received approval for clinical trials of a new drug [18] - SAIC Group's subsidiary plans to invest 666 million yuan in the restructuring of SAIC Hongyan [19] Group 5 - Hanwei Technology plans to sell 65% of Hanwei Zhiyuan for approximately 440 million yuan [20] - Xingtong Co. has been awarded new capacity for coastal inter-provincial bulk liquid hazardous goods transportation [21][22] Group 6 - EVE Battery Investment received a cash dividend of 375 million HKD from its associate company [23] - Shanmei International's chairman has resigned due to work changes [24] - Weiye Co.'s chairman has resigned for personal reasons [25] Group 7 - Jiao Da Sino's chairman has been placed under detention [26] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [27][28] - *ST Zhengping's stock has been suspended for investigation due to abnormal price fluctuations [29] Group 8 - Zhenray Technology's chairman has had detention measures lifted [30] - Shiming Technology's chairman has had detention measures changed to a warning [31] - Nanxin Pharmaceutical is under investigation by the CSRC for suspected violations in annual report disclosures [32] Group 9 - Daqian Ecology's shareholder plans to reduce holdings by up to 3% [33] - Rundar Medical's shareholders plan to reduce holdings by up to 2.99% [34][35] - Saili Medical's shareholder plans to reduce holdings by up to 2% [36] Group 10 - Huaxin Environmental plans to repurchase shares for 40 to 80 million yuan [37] - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [38] - Zhongwu Drone has signed a significant contract worth 615 million yuan for drone systems [39]

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [2] - Bee Assistant plans to raise up to 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [3] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] Group 2 - Three squirrels received approval from the China Securities Regulatory Commission for H-share issuance, planning to issue up to 81.5483 million shares [5] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [6] - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind and solar energy [7] Group 3 - Sainz's subsidiary plans to invest up to 300 million yuan in the expansion of selection and extraction agents [8] - Hunan YN reported no significant changes in its internal and external operating environment [9] - Electric Power Investment plans to restructure assets and has received a notice from the Shenzhen Stock Exchange to suspend review [10] Group 4 - Guanzhong Ecology is in the planning stage to acquire 51% of Hangzhou Actuary [11] - Aima Technology announced the transfer and suspension of production capacity at its subsidiary in Guangdong [12] - Fosun Pharma's subsidiary received approval for clinical trials of a new drug [13] Group 5 - EVE Battery Investment received a cash dividend of 375 million HKD from its indirect associate, Simoer International [14] - Shanmei International announced a change in its board leadership due to personnel changes [15] - Weiye Co. announced the resignation of its chairman for personal reasons [16] Group 6 - Jiaoda Sinuo's chairman is under detention, and the company has appointed a new acting chairman [17] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [18] - ST Zhengping's stock price has seen an abnormal increase, leading to a suspension for investigation [19] Group 7 - Daqian Ecology's shareholder plans to reduce its stake by up to 3% [20] - Rundat Medical's shareholders plan to collectively reduce their stake by up to 2.99% [21] - Seli Medical's shareholder plans to reduce its stake by up to 2% [22] Group 8 - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [23] - Zhongwu Drone signed a significant contract worth 615 million yuan for drone systems [24]

Core Points - Duori Pharmaceutical announced on September 30 that it received a notification from its controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., regarding a potential change in company control [1] - The company has applied for a trading suspension starting from September 29, 2025, with an expected duration of no more than two trading days [1] - As of the announcement date, the parties involved are actively advancing the transaction, but no formal agreement has been signed, leading to uncertainty about the resumption of trading on October 9, 2025 [1] - To ensure fair information disclosure and protect investor interests, the company has applied for an extension of the trading suspension, which is expected to last no more than three additional trading days [1]

Core Viewpoint - Duorui Pharmaceutical is facing significant challenges, including a potential change in control, declining revenue from its core product, and increasing financial burdens due to acquisitions. The company is exploring new growth avenues while grappling with a deteriorating financial situation [1][2][3][4][5][6][7]. Group 1: Control Change - Duorui Pharmaceutical's controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., is planning a change in control, which may lead to a shift in the company's actual controller [2][7]. - The stock was suspended from trading on September 29, 2025, with an expected suspension period of no more than three trading days [2][1]. - As of now, no formal agreements have been signed regarding the control change, and the outcome remains uncertain [2][7]. Group 2: Financial Performance - Duorui Pharmaceutical's revenue has significantly declined since its listing in 2021, with a projected revenue drop of nearly 50% by 2024 compared to its peak [3][4]. - The company reported a revenue of 1.07 billion yuan in the first half of 2025, a year-on-year decrease of 29.13%, and a net loss of 42.5 million yuan, which is a 1197.26% increase in losses compared to the previous year [4]. - The core product, sodium acetate Ringer's injection, has seen a drastic revenue decline, with sales dropping from 465 million yuan in 2021 to an estimated 12 million yuan in 2024 [3][4]. Group 3: Product Challenges - The sodium acetate Ringer's injection, which accounts for nearly 50% of the company's main business revenue in 2024, has faced declining sales due to policy changes such as medical insurance cost control and centralized procurement [3][4]. - The company has acknowledged the risk of having a single product structure, which has contributed to its financial struggles [3]. Group 4: Acquisition Strategy - To counteract declining revenues, Duorui Pharmaceutical has pursued acquisitions, including Hubei Xinchengda Chemical Co., Ltd. and Sichuan Duorui Pharmaceutical Co., Ltd., to diversify its revenue streams [5][6]. - In the first half of 2025, Hubei Xinchengda contributed 33.18 million yuan to the company's revenue, accounting for 31% of total revenue [5]. - The acquisition of Sichuan Duorui involved a significant financial commitment, leading to increased management, financial, and research expenses [6]. Group 5: Financial Burden - The company's financial obligations have increased, with total liabilities reaching 754 million yuan and an asset-liability ratio of 52.01% as of June 2025, up from 23.37% at the end of 2023 [6]. - To finance acquisitions, Duorui Pharmaceutical's subsidiary applied for a merger loan of up to 300 million yuan, with the company providing a guarantee [6].

Core Points - Duori Pharmaceutical (301075.SZ) is actively advancing its transaction discussions, with no formal agreement signed yet [1] - The company anticipates that it will not resume trading on October 9, 2025, due to uncertainties surrounding the transaction [1] - To ensure fair information disclosure and protect investor interests, the company has applied for a continued trading suspension, expected to last no more than three trading days [1]

Core Viewpoint - Duori Pharmaceutical (301075) announced on September 30, 2025, that it received a notification from its controlling shareholder, Tibet Jiakang Times Technology Development Co., Ltd., regarding a potential change in company control, which may lead to a change in the controlling shareholder and actual controller [1] Group 1 - The company is currently in discussions regarding the overall plan for the control change, and no formal agreements have been signed yet [1] - As a result of the ongoing negotiations, the company anticipates that it will not be able to resume trading on October 9, 2025, at market opening [1] - The company has applied to the Shenzhen Stock Exchange for an extension of its stock suspension, which is expected to last no more than three trading days [1]

Core Viewpoint - Duori Pharmaceutical (301075.SZ) is currently in negotiations regarding a transaction, with no formal agreement signed yet, leading to an expected continuation of stock suspension until at least October 9, 2025 [1] Summary by Relevant Sections - **Transaction Status** - The parties involved are actively advancing the transaction, but the overall plan is still under negotiation [1] - No formal agreement has been reached as of the announcement date [1] - **Stock Suspension** - The company anticipates that it will not resume trading on October 9, 2025, at the market opening [1] - Due to the uncertainties surrounding the transaction, the company has applied for an extension of the stock suspension, which is expected to last no more than three trading days [1]

关于筹划控制权变更进展暨继续停牌的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 西藏多瑞医药股份有限公司 证券代码：301075 证券简称：多瑞医药 公告编号：2025-076 鉴于上述事项存在不确定性，为保证公平信息披露，维护投资者 利益，避免公司股价异常波动，根据《深圳证券交易所上市公司自律 监管指引第 6 号——停复牌》的相关规定，经公司向深圳证券交易所 申请，公司股票（证券代码：301075，证券简称：多瑞医药）自 2025 年 10 月 9 日（星期四）上午开市起继续停牌，预计停牌时间不超过 3 个交易日。 公司将根据上述事项的进展情况，严格按照有关法律法规的规定 和要求履行信息披露义务。待上述事项确定后，公司将及时发布相关 公 告 并 申 请 复 牌 。 公 司 指 定 信 息 披 露 媒 体 为 巨 潮 资 讯 网 （www.cninfo.com.cn），公司所有信息均以在上述指定媒体刊登的信 息为准。敬请投资者关注后续公告，并注意投资风险。 特此公告。 西藏多瑞医药股份有限公司 董事会 控股股东西藏嘉康时代科技发展有限公司、实际控制人邓 ...